Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years Life Science Investing
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting Pharmaceutical Investing
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right Life Science Investing
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 Life Science Investing
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm Sublingual Film Pharmaceutical Investing
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy Life Science Investing
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Life Science Investing
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy Life Science Investing
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance Pharmaceutical Investing
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates Life Science Investing
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models Life Science Investing
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement Life Science Investing
